Company profile
Century Therapeutics, Inc.
NASDAQ: IPSC · Healthcare · Biotechnology
#340 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
48DFH 59DQ 23GM 67SS 48
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$9.6M
Employees
78
as of 2026-08-13
Market cap
$169.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$109.2M$109.2M2025
Net income-$9.6M-$9.6M2025
Operating income-$17.3M-$17.3M2025
Total assets$223.7M$223.7M2025
Liabilities$64.8M$64.8M2025
Equity$158.9M$158.9M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Century Therapeutics, Inc.’s revenue?
Century Therapeutics, Inc. booked $109.2M in FY2025 revenue, growing 1557% year over year — faster than 97% of Healthcare companies we track, at a -8.8% net margin.
Peers · Healthcare
Anika Therapeutics, Inc.74BUroGen Pharma Ltd.55COptimizeRx Corp.72BAuxly Cannabis Group Inc.76B+Theravance Biopharma Inc75B+Zevra Therapeutics, Inc.70BNeighbors
Philadelphia →Key facts
CEOBrent Pfeiffenberger
SectorHealthcare
IndustryBiotechnology
HeadquartersPhiladelphia, PA
ExchangeNASDAQ: IPSC
Employees78
IPO date2021-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.